Beam value: An indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin

BMJ Open Diabetes Research and Care

Volumn 4, Issue 1, 2016, Pages

  Zisman, Ariel ^a   Morales, Francienid ^b   Stewart, John ^c   Stuhr, Andreas ^d   Vlajnic, Aleksandra ^b   Zhou, Rong ^e  

^a Endocrine Center of Aventura   (United States)

^b SANOFI   (France)

^c Sanofi Canada   (Canada)

^d Bayer Diabetes Care   (United States)

^e Medpace ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN GLULISINE; ORAL ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BEAM VALUE; CLINICAL INDICATOR; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 85006226050     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2015-000171     Document Type: Article

References (27)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149.
2. Williamson C, Glauser TA, Burton BS, et al. Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices. Postgrad Med 2014;126: 145-160.
3. Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diab Sci Tech 2007;1:540-548.
4. Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26: 3080-3086.
5. Tanenberg RJ, Zisman A, Stewart JA. Glycaemia optimization treatment (GOT): glycaemic control and rate of severe hypoglycaemia for 5 different dosing algorithms of insulin glargine (GLAR) in patients with type 2 diabetes mellitus (T2DM). Diabetologia 2006;49(Suppl 1):601.
6. Rosenstock J, Davies M, Home PD, et al. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-416.
7. Tanenberg R, Zisman A, Stewart J. Glycemia Optimization Treatment (GOT): glycemic control and rate of severe hypoglycemia for five different dosing algorithms of insulin glargine (GLAR) in patients with type 2 diabetes mellitus (T2DM). Diabetes 2006;55 (Suppl 1):A135.
8. Shaefer C, Traylor L, Gao L, et al. Exploratory study of a dose- response curve for basal insulin. Diabetes 2015;64(Suppl 1):A253.
9. Edelman S, Dailey G, Flood T, et al. A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. Osteopath Med Prim Care 2007;1:9.
10. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881-885.
11. Garg S, Hirsch IB. Self-monitoring of blood glucose. Int J Clin Pract Suppl 2010;1-10.
12. Spollett G. Self-monitoring of blood glucose: an underutilized tool. Clinical Diabetes 2010;28:127-129.
13. Sorkin JD, Muller DC, Fleg JL, et al. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 2005;28:2626-2632.
14. Levitan EB, Song Y, Ford ES, et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147-2155.
15. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813-819.
16. Choi JH, Park CY, Cha BS, et al. Perception of clinicians and diabetic patients on the importance of postprandial glucose control and diabetes education status: a cross sectional survey. Diabetes Metab J 2012;36:120-127.
17. Ong WM, Chua SS, Ng CJ. Barriers and facilitators to self-monitoring of blood glucose in people with type 2 diabetes using insulin: a qualitative study. Patient Prefer Adherence 2014;8:237-246.
18. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas: the Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006;23:736-742.
19. Standl E, Maxeiner S, Raptis S, et al. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005;28:419-420.
20. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-259.
21. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008;371:1073-1084.
22. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451.
23. Lankisch MR, Ferlinz KC, Leahy JL, et al. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab 2008;10:1178-1185.
24. Davidson MB, Raskin P, Tanenberg RJ, et al. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract 2011;17:395-403.
25. Del Prato S, Nicolucci A, Lovagnini-Scher AC, et al. Telecare provides comparable efficacy to conventional self-monitored blood glucose in patients with type 2 diabetes titrating one injection of insulin glulisine-the ELEONOR study. Diabetes Technol Ther 2012;14:175-182.
26. Riddle M, Umpierrez G, DiGenio A, et al. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 2011;34:2508-2514.
27. Hamaty M. Insulin treatment for type 2 diabetes: when to start, which to use? Cleve Clin J Med 2011;78:332-342.